Literature DB >> 19816589

Lack of association of two polymorphisms of IRF5 with Behcet's disease.

Haijun Li1, Peizeng Yang, Zhengxuan Jiang, Shengping Hou, Lin Xie.   

Abstract

PURPOSE: Interferon regulation factor 5 (IRF5) is a member of the IRF family of transcription factors that control the transactivation of type I interferon system-related genes as well as the expression of several other genes involved in immune response. Here, we investigated its association with Behcet's disease (BD) in a well defined group of Chinese Han patients.
METHODS: A total of 152 unrelated Chinese patients with BD and 149 healthy blood donors were genotyped for IRF5rs2280714 and rs752637 polymorphisms. Genomic DNA was isolated from peripheral blood mononuclear cells. Genotyping of each single nucleotide polymorphism (SNPs) was performed by polymerase chain reaction restriction fragment length polymorphism (PCR-RFLP). Allele and genotype frequencies of IRF5rs2280714 and rs752637 polymorphisms were compared between patients and controls using a two-sided chi(2) test.
RESULTS: The results showed no significant difference concerning the frequency of the allele of rs2280714 and rs752637 polymorphisms between BD patients and the normal controls (p=0.647 and p=0.105, respectively). The frequencies of the genotype of rs2280714 and rs752637 were not different between BD patients and the normal controls (p=0.233 and, p=0.266, respectively). Clinical manifestation stratification analysis did not show any association of IRF5 polymorphisms with BD patients (p>0.05).
CONCLUSIONS: Our study revealed that the rs2280714 and rs752637 SNPs were not associated with the susceptibility to BD. There was no association between the two polymorphisms of IRF5 and any extraocular clinical manifestations in BD.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19816589      PMCID: PMC2759328     

Source DB:  PubMed          Journal:  Mol Vis        ISSN: 1090-0535            Impact factor:   2.367


Introduction

Behcet’s disease (BD) is a chronic autoimmune disease in which both genetic and environmental factors are involved. It is a common uveitis entity in China, Japan, and the Middle East countries [1]. BD is an autoimmune disease that results from damage to blood vessels throughout the body [2]. However, what triggers this reaction is unclear. The family of interferon regulatory factors (IRF) had been implicated in providing a principal basis for host resistance against pathogens [3]. The family also plays a role in the regulation of the development of the immune system and the production of pro-inflammatory cytokine [4-7]. Studies have demonstrated that IRF1 is associated with Behcet’s disease [8] whereas IRF5 has been found to be associated with certain autoimmune diseases such as systemic lupus erythematosus (SLE) [9,10], inflammatory bowel disease (IBD) [11], rheumatoid arthritis (RA) [12], and multiple sclerosis (MS) [13]. Whether there is an association of IRF5 with BD is not yet clear. Here, we examined the association of IRF5 single polymorphisms (rs2280714 and rs752637) with BD in a Chinese Han population.

Methods

Patients and normal controls

A total of 152 unrelated Chinese patients with BD according to the international study group criteria [14] and 149 age-, sex-, and ethnically-matched healthy controls were included in this study. Samples from patients and controls were genotyped for IRF5 rs2280714 and rs752637 polymorphisms after they all gave their informed consents. All study subjects were recruited from Zhongshan Ophthalmic Center (Sun Yat-sen University, Guangzhou, P.R. China), the First Affiliated Hospital, Chongqing Medical University (Chongqing, P.R. China), and Daping Hospital (the Third Military Medical University, Chongqing, P.R. China). The study was approved by the local ethics committees of the Third Military Medical University and Chongqing Medical University.

Genomic DNA extraction and PCR

Blood samples were collected in ethylenediamine tetra acetic acid (EDTA) tubes and kept at −70 °C until required [15]. Genomic DNA was extracted from peripheral blood mononuclear cells, which was performed by conventional salting of cellular protein, an alcohol precipitation using standard proteinase K digestion, and phenol chloroform extraction procedure [16]. We amplified the target DNA in IRF5 by polymerase chain reaction (PCR) using the relevant primers. The primers of the two remaining sites were designed using Primer Premier 5.0 software (Premier Biosoft International, Palo Alto, CA). The details of the primers and enzymes used for PCR-RFLP genotyping are presented in Table 1.
Table 1

The primers and enzymes used for PCR-RFLP genotyping.

SNPForward primer sequenceReverse primer sequenceEnzyme
rs2280714
5′-CGTGGTCACATTGGTGATGCTC-3′
5′-GGCTCTTCTCTCCAAGGCAGACA-3′
BSMFI
rs7526375′-AAGGTGCCCAGAAAGAAGCTTCTTAC-3′5′-GCACTGGGAAATCACCCCTTTT-3′BCEAI

The details of the primers and enzymes used for PCR-RFLP genotyping.

The details of the primers and enzymes used for PCR-RFLP genotyping. Each PCR was performed in 10 μl of solution containing 5 μl premix Taq (Takara Biotechnology Co. Ltd, Dalian, P.R. China), 10 pmol primers, and 0.2 μg of genomic DNA. The cycling profile was: initial denaturation at 94 °C for 4 min, 45 cycles consisting of 94 °C for 5 s, proper annealing temperature 63 °C for 30 s, 72 °C for 30 s, and a final extension for 4 min at 72 °C.

Genotyping

Genotyping of each single nucleotide polymorphism (SNP) was performed by PCR restriction fragment length polymorphism (PCR–RFLP). PCR products of rs2280714 and rs752637 were respectively digested with 2 μl of BSMFI, BCEAI restriction enzymes (Fermentas, MBI, Vilnius, Lithuania) in a 10 μl reaction volume overnight. Digestion products were visualized on agarose of 2%–3% concentration and stained with GoldviewTM (SBS Genetech, Beijing, P.R. China). BSMFI digestion of 130 bp PCR product of AA genotype gives two fragments, the GG gives one fragment, and the AG gives three fragments. BCEAI digestion of 120 bp PCR product of AA genotype gives two fragments, the GG gives one fragment, and the AG gives three fragments. To confirm the accuracy of the method employed, randomly selected subjects (20% of all samples) were analyzed by direct sequencing (Invitrogen Biotechnology Co., Guangzhou, P.R. China). An appropriate control was included in each typing run.

Statistical analysis

Allele and genotype frequencies of IRF5 rs2280714 and rs752637 polymorphisms were compared between patients and controls. Statistical analysis was performed with the SPSS version 10.0 for Windows (SPSS Inc., Chicago, IL). We evaluated the frequency of genotypes and alleles in this study using the χ2 test. The association of rs2280714 and rs752637 with the extraocular findings was evaluated by logistic regression and statistical significance was taken when p<0.05.

Results

The average age of the BD patients was 32.7±6.4 years and that of the healthy controls was 33.8±9.3 years. No statistical difference in the distribution of age was observed between BD patients and controls (p>0.05). One hundred and fifty-two patients and one hundred forty-nine normal controls were genotyped for two IRF5 SNPs. It is worthwhile to point out that some genotypes were missing for controls for rs752637 SNPs due to insufficient amount of DNA in some samples. The results showed that there was no deviation from the Hardy–Weinberg equilibrium (HWE). The genotype and allele frequencies of the rs2280714 SNPs in BD patients were not different from those in normal controls (p=0.233 and p=0.647, respectively; Table 2). A similar result was found for rs752637 SNP versus normal controls (p=0.266 and p=0.105, respectively; Table 2). Stratification analysis according to oral ulcer, genital ulcer, hypopyon, skin lesions, and arthritis did not show any association of IRF5 polymorphisms with these parameters (Table 3; p>0.05).
Table 2

Genotype and allele distributions of IRF5 rs2280714 and rs752637 polymorphisms in BD patients and controls.

IRF5 SNPsGenotype allelePatientsNormal controlsp valueOR (95%CI)
rs2280714
AA
51 (56.1)
60 (54.9)
0.233

 
AG
74 (66.7)
58 (65.3)
0.233

 
GG
27 (29.3)
31 (28.7)
0.233

 
A
176 (57.9)
178 (59.7)
0.647
0.927 (0.670–1.283)
 
G
128 (42.1)
120 (40.3)
0.647
1.079 (0.780–1.493)
rs752637
AA
64 (59.0)
49 (54.0)
0.266

 
AG
68 (68.4)
63 (62.6)
0.266

 
GG
20 (24.5)
27 (22.5)
0.266

 
A
196 (64.5)
161 (57.9)
0.105
1.319 (0.944–1.843)
 G108 (35.5)117 (42.1)0.1050.758 (0.543–1.059)

BD=Behcet’s disease, OR=odds ratio, 95% CI=95% confidence interval. The genotype and allele distributions of IRF5 rs2280714 and rs752637 polymorphisms in BD patients and controls. No significant differences of the genotype and allele distributions were found between patients and controls.

Table 3

The clinical manifestations of BD patients.

Clinical manifestationsNPercentage
Uveitis
152
1%
Oral ulcer
127
0.836%
Genital ulcer
64
0.421%
Hypopyon
41
0.27%
Skin lesions
84
0.553%
Arthritis430.283%

N=number of patients; BD=Behcet’s disease. This table summarizes the proportion of clinical manifestations in relation to the BD patients

BD=Behcet’s disease, OR=odds ratio, 95% CI=95% confidence interval. The genotype and allele distributions of IRF5 rs2280714 and rs752637 polymorphisms in BD patients and controls. No significant differences of the genotype and allele distributions were found between patients and controls. N=number of patients; BD=Behcet’s disease. This table summarizes the proportion of clinical manifestations in relation to the BD patients

Discussion

It has been demonstrated that both genetic and environmental factors are involved in the development of BD [17]. In this study, we investigated the association of IRF5 polymorphisms with BD in the Chinese Han population. Our study showed that rs2280714 and rs752637 were not associated with BD. There was no association between the polymorphisms of IRF5 with any extraocular clinical manifestations. BD is a common multisystem inflammation disorder characterized by recurrent oral and genital ulceration, multiple skin lesions and uveitis [18,19]. It has a distinctive geographical distribution. IRF5 has been shown to be strongly associated with certain autoimmune diseases in different ethnic populations [10,11,20,21] and to play a critical role in the pathogenesis of autoimmunity [22]. Therefore, this gene has been considered as a general susceptible gene for autoimmune diseases. However, the genetic factors associated with this disease in Chinese Han patients have been scarcely studied. In this study, we focused on the association of two SNPs of IRF5 with BD in the Chinese patients. As population stratification may lead to a false-positive result in a case-control study, we strictly selected the BD patients and controls with Chinese Han nationality. To validate the result of genotyping by PCR-RFLP, 20% of the samples were directly sequenced. Unfortunately, in this study, we did not find any association of rs2280714 and rs752637 SNPs with BD. A similar result was observed after stratification analysis based on extraocular features. These results are not consistent with those seen in other autoimmune diseases reported in European and some other Asian populations [10,12,20,21]. This could be explained by the fact that the etiology and pathogenesis of BD may be different from those of the other autoimmune diseases [2,18,19]. The other possibility could be that Chinese Han people may have a different genetic background from other ethnic populations [2,19]. Additionally, association of some other IRF5 SNPs should be tested in BD. Lee and coworkers found the association of IRF1 polymorphism with Behcet’s disease in Koreans [8]. Here, we failed to find the association of IRF5 with BD. The inconsistent result can be explained by the different immune function of IRF1 from IRF5. Both of them interact with MyD88, an adaptor for multiple innate immune receptors, but induce a distinctively different set of pro-inflammatory cytokines. These results suggest that IRF1 and IRF5 play different roles in the production of pro-inflammatory cytokine and the regulation of the development immune system, that is to say, different mechanisms may be induced by IRF1 than by IRF5 in the development of BD disease. In conclusion, our study revealed that the rs2280714 and rs752637 SNPs were not associated with the susceptibility to BD. There was no association between the two polymorphisms of IRF5 with any clinical manifestations. Further studies are needed to investigate the association of other SNPs in IRF5 with BD.
  22 in total

1.  International diagnostic criteria and delay of diagnosis in Behçet's disease.

Authors:  M D Mignogna; S Fedele; L Lo Russo
Journal:  J Rheumatol       Date:  2000-11       Impact factor: 4.666

2.  The interferon regulatory factor, IRF5, is a central mediator of toll-like receptor 7 signaling.

Authors:  Annett Schoenemeyer; Betsy J Barnes; Margo E Mancl; Eicke Latz; Nadege Goutagny; Paula M Pitha; Katherine A Fitzgerald; Douglas T Golenbock
Journal:  J Biol Chem       Date:  2005-01-28       Impact factor: 5.157

Review 3.  The interferon system and interferon regulatory factor transcription factors -- studies from gene knockout mice.

Authors:  M Sato; T Taniguchi; N Tanaka
Journal:  Cytokine Growth Factor Rev       Date:  2001 Jun-Sep       Impact factor: 7.638

4.  Clinical patterns and characteristics of uveitis in a tertiary center for uveitis in China.

Authors:  Peizeng Yang; Zhen Zhang; Hongyan Zhou; Bing Li; Xiangkun Huang; Yang Gao; Liangxiang Zhu; Yalin Ren; Jan Klooster; Aize Kijlstra
Journal:  Curr Eye Res       Date:  2005-11       Impact factor: 2.424

5.  Epidemiology and clinical course of Behçet's disease in the Reggio Emilia area of Northern Italy: a seventeen-year population-based study.

Authors:  Carlo Salvarani; Nicolò Pipitone; Maria Grazia Catanoso; Luca Cimino; Bruno Tumiati; Pierluigi Macchioni; Gianluigi Bajocchi; Ignazio Olivieri; Luigi Boiardi
Journal:  Arthritis Rheum       Date:  2007-02-15

6.  Analysis of IRF5 gene functional polymorphisms in rheumatoid arthritis.

Authors:  Blanca Rueda; M V Prasad Linga Reddy; Miguel A González-Gay; Alejandro Balsa; Dora Pascual-Salcedo; Ingemar F Petersson; Alicia Eimon; Sergio Paira; Hugo R Scherbarth; Bernardo A Pons-Estel; Maria F González-Escribano; Marta E Alarcón-Riquelme; Javier Martín
Journal:  Arthritis Rheum       Date:  2006-12

7.  [Concern on the changes of clinical pattern and etiological factors in uveitis in China].

Authors:  Pei-zeng Yang
Journal:  Zhonghua Yan Ke Za Zhi       Date:  2008-10

8.  Interferon regulatory factor 5, a novel mediator of cell cycle arrest and cell death.

Authors:  Betsy J Barnes; Merrill J Kellum; Karen E Pinder; J Augusto Frisancho; Paula M Pitha
Journal:  Cancer Res       Date:  2003-10-01       Impact factor: 12.701

9.  Multiple regulatory domains of IRF-5 control activation, cellular localization, and induction of chemokines that mediate recruitment of T lymphocytes.

Authors:  Betsy J Barnes; Merrill J Kellum; Ann E Field; Paula M Pitha
Journal:  Mol Cell Biol       Date:  2002-08       Impact factor: 4.272

10.  Role of IFN regulatory factor 5 transcription factor in antiviral immunity and tumor suppression.

Authors:  Hideyuki Yanai; Hui-Min Chen; Takayuki Inuzuka; Seiji Kondo; Tak W Mak; Akinori Takaoka; Kenya Honda; Tadatsugu Taniguchi
Journal:  Proc Natl Acad Sci U S A       Date:  2007-02-20       Impact factor: 11.205

View more
  2 in total

Review 1.  The genetics of Behçet's disease in a Chinese population.

Authors:  Shengping Hou; Aize Kijlstra; Peizeng Yang
Journal:  Front Med       Date:  2012-11-15       Impact factor: 4.592

2.  Two functional variants of IRF5 influence the development of macular edema in patients with non-anterior uveitis.

Authors:  Ana Márquez; María Carmen Cénit; Miguel Cordero-Coma; Norberto Ortego-Centeno; Alfredo Adán; Alejandro Fonollosa; David Díaz Valle; Esperanza Pato; Ricardo Blanco; Joaquín Cañal; Manuel Díaz-Llopis; Enrique de Ramón; María José Del Rio; José Luis García Serrano; Joseba Artaraz; José Manuel Martín-Villa; Víctor Llorenç; Marina Begoña Gorroño-Echebarría; Javier Martín
Journal:  PLoS One       Date:  2013-10-07       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.